Origin Materials (ORGN) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Signed first major PET caps customer MOU, expected to generate over $100 million in revenue over two years starting early 2025, with significant ramp in 2026.
Commercial-scale PET cap production is on track for Q4 2024, with revenue ramping in Q1 2025.
Announced mass production partnerships in Europe (Bachmann Group) and North America (Reed City Group) to support PET cap manufacturing and geographic expansion.
Over 1 million PET caps produced to date; manufacturing systems validated for quality.
Reaffirmed pathway to profitability without need for additional equity capital.
Financial highlights
Q2 2024 revenue was $7.0 million, up slightly from $6.9 million in Q2 2023, mainly from supply chain activation.
Net loss for Q2 2024 was $19.5 million, compared to $6.5 million in Q2 2023.
Adjusted EBITDA loss for Q2 2024 was $12.9 million, compared to $11.7 million in Q2 2023.
Cash, cash equivalents, and marketable securities totaled $132.1 million as of June 30, 2024.
2024 full-year revenue guidance remains $25–$35 million; net cash burn expected between $55–$65 million.
Outlook and guidance
Caps and closures business expected to generate significant, recurring revenue and gross profit starting in 2025.
EBITDA loss projected to decline significantly in 2025, with positive EBITDA expected between 18–24 months from now.
No additional equity capital raise anticipated; current cash runway deemed sufficient to reach profitability.
Management expects continued operating losses in the near term as the company invests in scaling operations and developing new products.
Additional customer agreements and operational updates expected in the coming months.
Latest events from Origin Materials
- Stockholders will vote on a plan to dissolve the company and distribute $0.61–$3.54 per share.ORGN
Proxy filing15 May 2026 - Stockholders will vote on a proposed dissolution, with estimated payouts of $0.61–$3.48 per share.ORGN
Proxy filing14 May 2026 - Dissolution plan approved, operations winding down, and Q1 revenue fell 91% year-over-year.ORGN
Q1 202614 May 2026 - Breakeven delayed to 2028 as PET cap commercialization progresses amid urgent liquidity needs.ORGN
Q4 202527 Mar 2026 - Stockholders approved a reverse split and major share issuance, advancing strategic milestones.ORGN
EGM 202618 Feb 2026 - Strong PET cap demand, $100M+ MOU, and EBITDA positivity targeted for 1H 2026.ORGN
Q3 202414 Jan 2026 - Rapid transformation to PET caps leverages technical strengths, innovation, and scalable growth.ORGN
Fireside Chat9 Jan 2026 - Key votes on reverse stock split and major share issuance set for February 2026.ORGN
Proxy Filing6 Jan 2026 - Approval sought for reverse split and convertible note share issuance to support listing and funding.ORGN
Proxy Filing6 Jan 2026